R&B Biotech

Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64 million) in a Series A+ financing round. The round was led by SDIC Venture Capital, with participation from Panlin Capital, Essence Fund’s healthcare fund, and existing investor Loyal Valley Capital. The proceeds will be allocated…